At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
Camostat Mesilate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Camostat Mesilate Compared to Standard of Care in Subjects With Mild-Moderate COVID-19
In Brief
A Phase 2 clinical trial evaluating Camostat Mesilate, Placebo, and 1 other intervention for Covid19. Completed, enrolled 49 participants across 1 site.
Detailed Summary
This study will evaluate the efficacy of oral Foipan® (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with mild-moderate COVID-19 disease. Patients will attend 4 study visits over a period of up to 28 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartDec 2020
Primary CompletionMay 2021
TodayJul 2026
First PostedAug 24, 2020
Enrollment StartDec 19, 2020
Primary CompletionMay 15, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.9 years ago
Interventions
Camostat Mesilatedrug
Camostat Mesilate administered as oral tablets
Placebodrug
Placebo to match camostat mesilate
Standard of Care Treatmentother
Standard of Care Treatment for COVID-19 Infection